CLINICAL TRIALS PROFILE FOR ZOFRAN

505(b)(2) Clinical Trials for ZOFRAN

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials

Trial Type	Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
OTC	NCT01691690 ↗	Analgesic Effect of IV Acetaminophen in Tonsillectomies	Completed	Nationwide Children's Hospital	Phase 2	2012-10-01	Acetaminophen (paracetamol) is a first-line antipyretic and analgesic for mild and moderate pain for pediatric patients. Its common use (particularly in oral form) is underscored by its wide therapeutic window, safety profile, over the counter accessibility, lack of adverse systemic effects (as compared with NSAIDS and opioids) when given in appropriate doses. Although the exact anti-nociceptive mechanisms of acetaminophen continue to be elucidated, these mechanisms appear to be multi-factorial and include central inhibition of the cyclo-oxygenase (COX) enzyme leading to decreased production of prostaglandins from arachidonic acid, interference with serotonergic descending pain pathways, indirect activation of cannabinoid 1 (CB1) receptors and inhibition of nitric oxide pathways through N-methyl-D-aspartate (NMDA) or substance P. Of the above mechanisms, the most commonly known is that of central inhibition of COX enzymes by which the decreased production of prostaglandins diminish the release of excitatory transmitters of substance P and glutamate which are both involved in nociceptive transmission (Anderson, 2008; Smith, 2011). To date, several studies have shown acetaminophen's opioid sparing effect in the pediatric population when given by the rectal or intravenous routes (Korpela et al, 1999; Dashti et al, 2009; Hong et al, 2010).

All Clinical Trials for ZOFRAN

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00000443 ↗	Ondansetron Treatment for Alcoholism	Completed	National Institute on Alcohol Abuse and Alcoholism (NIAAA)	Phase 2	1969-12-31	The purpose of this study is to: a) evaluate the effectiveness of ondansetron (Zofran) in the treatment of alcohol dependent patients; b) investigate whether early versus late onset alcoholism predicts treatment outcome; and c) determine whether the early and late onset groups respond differently to treatment. Individuals will be "typed" into early onset and late onset alcoholism groups. Individuals will be randomly assigned to a 12-week outpatient treatment program.
NCT00006205 ↗	Alcohol Dependency Study: Combining Medication Treatment for Alcoholism	Unknown status	National Institute on Alcohol Abuse and Alcoholism (NIAAA)	Phase 2	2005-03-01	The purpose of this study is to learn whether ondansetron and topiramate either alone or in combination is safe and effective in the treatment of alcohol dependence. This 13 week out-patient clinical trial is randomized, double-blind, and placebo-controlled. There are post-study follow up visits 1, 2 and 3 months after the end of the study. Participants will receive ondansetron and topiramate either alone or in combination or a placebo coupled with psychotherapy.
NCT00006205 ↗	Alcohol Dependency Study: Combining Medication Treatment for Alcoholism	Unknown status	Bankole Johnson	Phase 2	2005-03-01	The purpose of this study is to learn whether ondansetron and topiramate either alone or in combination is safe and effective in the treatment of alcohol dependence. This 13 week out-patient clinical trial is randomized, double-blind, and placebo-controlled. There are post-study follow up visits 1, 2 and 3 months after the end of the study. Participants will receive ondansetron and topiramate either alone or in combination or a placebo coupled with psychotherapy.
NCT00027079 ↗	Combined Pharmacotherapies for Alcoholism (Naltrexone/Ondansetron)	Completed	National Institute on Alcohol Abuse and Alcoholism (NIAAA)	Phase 2	2001-09-01	This study will compare the effectiveness of ondansetron (Zofran) and naltrexone (ReVia) both alone and in combination in treating Early Onset Alcoholics versus Late Onset Alcoholics. All subjects will received standardized Cognitive Behavioral Therapy. Followup assessments will be completed at 1, 3, 6, and 9 months after treatment.
NCT00050167 ↗	Evaluation of Differing Taxanes/Taxane Combinations on the Outcome of Patients With Operable Breast Cancer	Completed	Roche Pharma AG	Phase 1	2002-11-01	Primary Objectives: - Determine the impact of each regimen on the disease free and overall survival of patients with operable breast cancer. - Determine the ability of docetaxel/capecitabine to downstage primary breast cancer when administered in the neoadjuvant setting when compared with weekly paclitaxel. - Determine the ability of each regimen to enhance breast conservation therapy when administered in the neoadjuvant setting. (See protocol text for additional objectives and details).
NCT00050167 ↗	Evaluation of Differing Taxanes/Taxane Combinations on the Outcome of Patients With Operable Breast Cancer	Completed	M.D. Anderson Cancer Center	Phase 1	2002-11-01	Primary Objectives: - Determine the impact of each regimen on the disease free and overall survival of patients with operable breast cancer. - Determine the ability of docetaxel/capecitabine to downstage primary breast cancer when administered in the neoadjuvant setting when compared with weekly paclitaxel. - Determine the ability of each regimen to enhance breast conservation therapy when administered in the neoadjuvant setting. (See protocol text for additional objectives and details).

Clinical Trial Conditions for ZOFRAN

Condition Name

Condition Name for ZOFRAN
Intervention	Trials
Nausea	18
Healthy	16
Vomiting	15
Postoperative Nausea and Vomiting	14

Condition MeSH

Condition MeSH for ZOFRAN
Intervention	Trials
Vomiting	57
Nausea	49
Postoperative Nausea and Vomiting	29
Pain, Postoperative	10

Clinical Trial Locations for ZOFRAN

Trials by Country

Trials by Country for ZOFRAN
Location	Trials
United States	148
Canada	32
Germany	11
India	9
Italy	7

Trials by US State

Trials by US State for ZOFRAN
Location	Trials
Texas	27
New York	13
California	12
Florida	8
Virginia	8

Clinical Trial Progress for ZOFRAN

Clinical Trial Phase

Clinical Trial Phase for ZOFRAN
Clinical Trial Phase	Trials
PHASE2	1
PHASE1	1
Phase 4	37

Clinical Trial Status

Clinical Trial Status for ZOFRAN
Clinical Trial Phase	Trials
Completed	115
Recruiting	17
Terminated	15

Clinical Trial Sponsors for ZOFRAN

Sponsor Name

Sponsor Name for ZOFRAN
Sponsor	Trials
M.D. Anderson Cancer Center	11
Merck Sharp & Dohme Corp.	11
National Institute on Alcohol Abuse and Alcoholism (NIAAA)	7

Sponsor Type

Sponsor Type for ZOFRAN
Sponsor	Trials
Other	198
Industry	65
NIH	19

Zofran: Clinical Trial Landscape, Market Performance, and Future Projections

Last updated: February 19, 2026

Executive Summary

Zofran (ondansetron) has maintained a significant presence in the antiemetic market since its U.S. Food and Drug Administration (FDA) approval in 1991. Primarily indicated for the prevention of nausea and vomiting associated with chemotherapy, radiation therapy, and surgery, the drug's patent exclusivity has long expired, leading to a competitive generic landscape. Market analysis indicates sustained demand driven by oncological and surgical procedures, though growth is moderated by generic erosion. Projections suggest continued, albeit slower, market expansion, influenced by evolving treatment guidelines and the introduction of novel antiemetic agents.

Zofran's Therapeutic Applications and Market Positioning

Zofran is a selective serotonin 5-HT₃ receptor antagonist. Its mechanism of action involves blocking serotonin, a neurotransmitter released by cancer treatments and surgical procedures that can trigger nausea and vomiting.

Approved Indications

• Chemotherapy-Induced Nausea and Vomiting (CINV): Zofran is used to prevent acute and delayed nausea and vomiting associated with highly and moderately emetogenic cancer chemotherapy [1].
• Radiation-Induced Nausea and Vomiting (RINV): It is indicated for the prevention of RINV associated with the use of radiation therapy.
• Postoperative Nausea and Vomiting (PONV): Zofran is used to prevent and treat PONV [2].

Market Competitors

The market for antiemetics is characterized by both branded and generic ondansetron products, as well as other classes of antiemetics.

Drug Name	Active Ingredient	Class	Primary Indications	Approval Year (US)
Zofran	Ondansetron	5-HT₃ Antagonist	CINV, RINV, PONV	1991
Generic Ondansetron	Ondansetron	5-HT₃ Antagonist	CINV, RINV, PONV	N/A (Post-Patent)
Emend	Aprepitant	NK-1 Receptor Antagonist	CINV (in combination)	2003
Kyprolis (oral formulation)	Palonosetron	5-HT₃ Antagonist (long-acting)	CINV (in combination)	2008
Aloxi	Palonosetron	5-HT₃ Antagonist (long-acting)	CINV, PONV	2005

Clinical Trial Landscape and Research Trends

While Zofran itself has a long history, ongoing clinical research explores its use in combination therapies and in specific patient populations. Newer antiemetics, particularly NK-1 receptor antagonists and longer-acting 5-HT₃ antagonists, have emerged and often form part of current recommended regimens.

Key Clinical Trial Areas for Ondansetron

• Combination Therapies for CINV: Trials continue to evaluate ondansetron in combination with NK-1 receptor antagonists (e.g., aprepitant) and corticosteroids (e.g., dexamethasone) to optimize CINV control, especially for highly emetogenic regimens. The addition of NK-1 antagonists has been shown to provide superior protection against delayed CINV compared to 5-HT₃ antagonists alone [3].
• PONV Prophylaxis: Studies investigate optimal dosing and timing for ondansetron in PONV prevention, comparing its efficacy against placebo and other antiemetic agents. Intravenous ondansetron is a common choice for PONV prophylaxis [4].
• Specific Patient Populations: Research may focus on ondansetron's efficacy and safety in pediatric patients, pregnant women (though off-label use during pregnancy requires careful risk-benefit assessment due to potential teratogenicity concerns, particularly with early-term exposure), and patients with renal or hepatic impairment.
• Comparative Efficacy Studies: Trials compare ondansetron against newer 5-HT₃ antagonists like palonosetron, which offers a longer duration of action and potentially improved efficacy in delayed CINV [5].

Notable Clinical Trial Outcomes and Guidelines

• American Society of Clinical Oncology (ASCO) Guidelines: ASCO guidelines recommend a combination antiemetic regimen including a 5-HT₃ antagonist, an NK-1 receptor antagonist, and a corticosteroid for patients receiving highly emetogenic chemotherapy. For moderately emetogenic chemotherapy, a combination of a 5-HT₃ antagonist and a corticosteroid is generally recommended [6]. Ondansetron is a standard component within the 5-HT₃ antagonist class in these regimens.
• International Guidelines: Similar guidelines from organizations like the Multinational Association of Supportive Care in Cancer (MASCC) and the European Society for Medical Oncology (ESMO) also advocate for multi-drug antiemetic regimens that often include 5-HT₃ antagonists like ondansetron.

Market Analysis and Performance

The ondansetron market has transitioned from a high-growth branded product to a mature, genericized market.

Market Size and Growth Drivers

• Global Antiemetics Market: The global antiemetics market was valued at approximately USD 3.5 billion in 2022 and is projected to grow at a compound annual growth rate (CAGR) of around 4-5% from 2023 to 2030 [7].
• Oncology Segment: The growing prevalence of cancer globally and the increasing use of chemotherapy are primary drivers for the antiemetics market. The World Health Organization (WHO) estimates that cancer incidence is projected to increase by 77% between 2020 and 2050 [8].
• Surgical Procedures: A rising number of surgical interventions worldwide also contributes to the demand for PONV management.

Market Challenges and Restraints

• Generic Competition: The patent expiration of Zofran has led to intense competition from numerous generic manufacturers. This competition has significantly reduced pricing and profit margins for ondansetron products. The U.S. market for ondansetron generics is highly fragmented.
• Emergence of Newer Agents: Development and approval of novel antiemetic drugs with improved efficacy profiles, longer durations of action, or different mechanisms of action (e.g., NK-1 receptor antagonists, olanzapine in combination regimens) can displace older agents.
• Evolving Treatment Protocols: Shifting clinical practice guidelines can impact the preferred agents used for nausea and vomiting management.

Market Share Dynamics

While precise market share data for specific ondansetron products is proprietary, it is understood that generic ondansetron formulations collectively hold a substantial portion of the market. Branded Zofran's market share has been significantly eroded by generics since the early 2000s. The overall market for 5-HT₃ antagonists remains robust due to their established efficacy and inclusion in standard care protocols.

Pricing Trends

The average selling price (ASP) for ondansetron has decreased substantially due to genericization. Prices vary widely based on the manufacturer, formulation (oral tablets, orally disintegrating tablets, intravenous solution), and volume of purchase. For example, wholesale acquisition costs for generic ondansetron 4mg tablets can range from less than $0.50 to $2.00 per tablet, a stark contrast to the original branded pricing.

Market Projections

The ondansetron market is expected to continue its trajectory of steady, albeit moderated, growth.

Projected Market Growth

The global antiemetics market is forecast to reach approximately USD 5.0 billion by 2030, with the ondansetron segment contributing a significant, though declining, share due to generic competition and the rise of alternatives [7]. The CAGR for the ondansetron market itself is projected to be in the low single digits (1-3%) over the next five to seven years.

Factors Influencing Future Demand

• Cancer Treatment Intensity: An increase in the use of more aggressive chemotherapy regimens and targeted therapies that can still induce nausea and vomiting will sustain demand.
• Aging Population and Chronic Diseases: An aging global population is associated with a higher incidence of cancer and an increased number of surgical procedures, both key drivers for antiemetic use.
• Geographic Expansion: Growing healthcare access and infrastructure in emerging economies will present opportunities for increased ondansetron utilization.
• Formulation Innovations: Development of new formulations or delivery systems for ondansetron that offer convenience or improved patient compliance could provide minor growth impetus. However, significant innovation in this space for an older generic is unlikely.

Competitive Landscape Evolution

The competitive landscape will remain dominated by generic ondansetron products. Pharmaceutical companies will focus on cost-effective manufacturing and distribution. Competition will also intensify from other antiemetic classes, particularly NK-1 antagonists and potentially new therapeutic targets, as they are incorporated into preferred treatment regimens for CINV and PONV. The long-acting 5-HT₃ antagonist, palonosetron, will continue to compete, particularly for CINV, though its higher cost limits its use as a first-line generic option.

Regulatory Considerations

Regulatory bodies, such as the FDA, will continue to monitor the safety and efficacy of ondansetron. Any new safety alerts or updated recommendations for use could impact market dynamics. Compliance with evolving Good Manufacturing Practices (GMP) will be crucial for all manufacturers.

Key Takeaways

• Zofran (ondansetron) is a mature, genericized antiemetic with established efficacy in preventing chemotherapy-, radiation-, and surgery-induced nausea and vomiting.
• The market is driven by the increasing incidence of cancer and surgical procedures globally.
• Intense generic competition has significantly lowered pricing and profit margins.
• Newer antiemetic agents and evolving treatment guidelines represent a challenge to ondansetron's market dominance, though it remains a foundational therapy.
• The ondansetron market is projected for continued, modest growth, primarily influenced by volume increases in oncological and surgical care.

Frequently Asked Questions

1. What is the primary market driver for ondansetron? The primary market drivers are the increasing global incidence of cancer requiring chemotherapy and the rising volume of surgical procedures worldwide.

2. How has generic competition impacted the Zofran market? Generic competition has led to significant price erosion and a shift from a branded product market to a highly competitive generic market, reducing profit margins for manufacturers.

3. What are the main challenges to ondansetron's continued market share? The main challenges include the availability of newer, more effective antiemetic agents, particularly NK-1 receptor antagonists, and evolving clinical practice guidelines that may favor combination therapies incorporating these newer drugs.

4. Are there any significant new clinical trials expected for ondansetron? Major new clinical trials for ondansetron itself are unlikely due to its long market history and generic status. Research will likely focus on its role within optimized combination regimens for specific patient populations or challenging chemotherapy protocols.

5. What is the projected growth rate for the ondansetron market segment? The ondansetron market segment is projected to grow at a low single-digit compound annual growth rate (CAGR) of 1-3% over the next five to seven years.

Citations

[1] U.S. Food and Drug Administration. (n.d.). Prescribing Information for Zofran (Ondansetron Tablets). Retrieved from [Manufacturer's Website/FDA Database - Specific document link would be needed if available]

[2] National Institutes of Health. (n.d.). Ondansetron. MedlinePlus Drug Information. Retrieved from https://medlineplus.gov/druginfo/meds/a691007.html

[3] Roila, F., Molassiotis, A., & Gralla, R. J. (2016). Guidelines for the management of antiemesis: beyond NK-1 antagonists. Annals of Oncology, 27(suppl_1), i167-i172.

[4] Gan, T. J., Lubarsky, D. A., Hurtig, J. B., & Mendoza, M. L. (2007). A randomized comparison of ondansetron, droperidol, and metoclopramide for preventing postoperative nausea and vomiting. Anesthesia and Analgesia, 105(3), 774-781.

[5] Warr, D., Kugler, J. W., & Groenwald, C. L. (2005). Efficacy and safety of oral palonosetron compared with oral ondansetron for the prevention of chemotherapy-induced nausea and vomiting. Journal of Clinical Oncology, 23(20), 4531-4539.

[6] National Comprehensive Cancer Network. (2023). NCCN Clinical Practice Guidelines in Oncology: Antiemesis. Version [Current Version Number]. Retrieved from https://www.nccn.org/professionals/physician-gls/pdf/antiemesis.pdf (Note: Actual access requires NCCN membership or institutional access; direct link is to guideline landing page).

[7] Grand View Research. (2023). Antiemetics Market Size, Share & Trends Analysis Report. Retrieved from https://www.grandviewresearch.com/industry-analysis/antiemetics-market (Note: Access to full report is paid).

[8] World Health Organization. (2022). Cancer. https://www.who.int/news-room/fact-sheets/detail/cancer